Proactive Investors - Run By Investors For Investors

Silence Therapeutics promotes Sedgwick to CEO role; Christély resigns

Silence Therapeutics promotes Sedgwick to CEO role; Christély resigns

Gene silencing specialist Silence Therapeutics (LON:SLN) announced today that Tony Sedgwick has been appointed the new CEO of the company following the resignation of Thomas Christély.

Sedgwick was formerly the chief business officer and his promotion takes effect immediately, the firm said.

Christély has resigned as a director for personal reasons but will ensure a smooth transition, the company added.

The company's chairman Jerry Randall said: "Tony has a great deal of relevant experience gained from the global pharmaceutical industry. He has made a very positive impact on Silence since joining in September last year and has demonstrated the right leadership skills needed as the company continues to gain momentum."

He thanked Christély for his many years of valuable service, on behalf of the board, and wished him well for the future.

New chief executive Sedgwick said that since joining the company, he had been excited about the opportunities ahead.

"We have already strengthened the business development team with the appointment of Dr Georg Buchner who will now take full responsibility for business development.

"The company's pipeline including Atu027 is making good progress and is endorsed by external partners," he said.

He added that in the next few years, he planned to increase the commercial focus of the company.

The company develops siRNAs, which are double-stranded molecules that silence certain genes. These are being developed to be used in targeting multiple disease types, including cancer.

Last month, the company announced a collaboration agreement with
US–based firm miRagen to assess delivery methods for new, micro versions of gene silencing technology to treat serious diseases.

Why Invest In Silence Therapeutics? Read More Here

Register here to be notified of future SLN Company articles
View full SLN profile

Silence Therapeutics Timeline

Related Articles

November 04 2015
The study, being carried out with the help of clinical research firm Simbec-Orion, will take place at 45 different sites – 10 in the US, 35 in Europe.
March 05 2015

The pace of progress has ramped up several notches in the past year at Nanobiotix, developer of a nano-medical technology that promises a revolution in radiotherapy.

September 29 2015
With a very strong balance sheet, Silence Therapeutics is now perfectly positioned, according to CEO Ali Mortazavi

© Proactive Investors 2015

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.